

**PATENT AGENT**

Portland Office
503.473.0911
susan.alpert.siegel@klarquist.com

EDUCATION

Ph.D., Genetics, State University of New York, Stonybrook, 1995

Ph.D. candidate, Toxicology, Toxicology Program, Department of Applied Biological Sciences, Massachusetts Institute of Technology, 1993

B.S. with Highest Honors in Environmental Toxicology, Departmental Citation, University of California, Davis, 1982

ADMISSIONS

U.S. Patent and Trademark Office, 1998 (Reg. No. 43,121)

PRACTICE AREAS

Patents

TECHNOLOGIES

Life Sciences & Biotechnology

Agriculture & Food Science

Green Technology & Renewable Energy

Susan Alpert Siegel, Ph.D.

Susan is a patent agent in the firm's Biotechnology and Life Sciences group, where she prepares and prosecutes U.S., foreign, and international patent applications. Over her career, she has written and successfully prosecuted hundreds of patent applications related to monoclonal antibodies, stem cells, genetic recombination methods, diagnostic assays, vaccines, anti-viral agents, immunotherapeutic treatment methods, viral vectors, pharmaceuticals, medical devices, cancer treatment, nutraceuticals and tissue culture methods. Her range of experience includes the management of Oppositions filed by international third parties, including patents on high value pharmaceuticals and treatment methods.

Susan earned her Ph.D. in molecular genetics, and completed post-doctoral fellowships in cancer biology at the University of California, San Francisco, and immunology at Stanford University. She then conducted academic research in the field of transplant rejection. Following her academic career, but prior to joining Klarquist, she was employed as a patent agent at a large intellectual property firm.

Susan's depth of knowledge and broad technical aptitude enable her to deliver exceptional service to her clients. She is active in the bioscience community, and has participated as a panelist and presenter at a number of national conferences over the course of her career. She has been a guest lecturer at the National Institutes of Health and the Centers for Disease Control and Prevention, and a variety of research institutions and universities.

Susan joined the firm as a patent agent in 1999.

Professional Experience

- Fish & Richardson
Menlo Park, California
Technology Specialist
- Stanford University Medical Center
Stanford, California
Senior Research Scientist, Cardiovascular Medicine
- Howard Hughes Medical Institute, Stanford University
Medical Center
Stanford, California
Post-doctoral Fellow (Irvington Institute Fellowship)

- University of California
San Francisco, California
Post-doctoral Fellow (National Institutes of Health Fellowship)

Presentations & Publications

- “Into the Darkness: Patent Eligibility of Natural Products,” National Institutes of Health, 2014
- “Changes in Patent Law Affecting the Biosciences Industry,” Oregon Bioscience Association, 2014
- Opportunities and Obstacles in the Commercialization of Induced Pluripotent Stem Cells,” AUTM 2014 Annual Meeting
- Panelist, “Commercialization of induced pluripotent stem cells,” AUTM 2013 Annual Meeting
- “Genes, Biologics, Biomarkers...Are they patentable?” Emory University, 2012
- Patenting Antibodies in the Shadow of Uncertainty, 4th Protein Discovery & Therapeutics Conference, 2011
- America Invents Act and Its Effect on Patent Prosecution, University of Pittsburgh, 2011

Representative Patents

- Hyposialylation disorders (WO 14/160018)
- Methods for treating a tumor using an antibody that specifically binds GRP94 (8,771,687)
- Defensin-antigen fusion proteins (8,754,030)
- Method of preparing a muscadine pomace extract (8,512,771)
- Humanized monoclonal antibodies that specifically bind and/or neutralize Japanese encephalitis virus (JEV) and their use (8,506,961)
- Methods of altering an immune response induced by CpG oligodeoxynucleotides (8,470,342)
- Methods of altering an immune response induced by CpG oligodeoxynucleotides (7,892,569)
- Use of Endostatin peptides for the treatment of fibrosis (8,716,232)
- Use of Endostatin peptides for the treatment of fibrosis (8,507,441)
- Method for enhancing stem cell trafficking (8,414,881)
- Soluble CD117 (sc-kit) for diagnosis of preeclampsia and eclampsia (8,518,716)
- Detection of infectious prion protein by seeded conversion of recombinant prion protein (EP 2,179,293)
- Molecular identification of Aspergillus species (7,384,741)
- Purification of biological preparations (6,310,186)